Wall Street analysts expect that Mylan NV (NASDAQ:MYL) will post sales of $3.25 billion for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Mylan’s earnings, with estimates ranging from $3.20 billion to $3.28 billion. Mylan reported sales of $3.08 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.5%. The business is expected to issue its next earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Mylan will report full year sales of $11.56 billion for the current financial year, with estimates ranging from $11.50 billion to $11.59 billion. For the next financial year, analysts expect that the company will report sales of $11.99 billion, with estimates ranging from $11.82 billion to $12.17 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Mylan.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.14 by $0.03. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3.01 billion. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 EPS.
MYL opened at $19.29 on Monday. The business’s 50-day moving average price is $18.31 and its two-hundred day moving average price is $18.86. Mylan has a 1 year low of $16.63 and a 1 year high of $32.23. The company has a market capitalization of $9.75 billion, a price-to-earnings ratio of 4.21, a P/E/G ratio of 1.02 and a beta of 1.71. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84.
In other news, insider Goulds Bruce 8,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 8th. Corporate insiders own 0.81% of the company’s stock.
A number of hedge funds have recently made changes to their positions in MYL. Advisory Services Network LLC raised its holdings in shares of Mylan by 170.0% in the 2nd quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock valued at $29,000 after purchasing an additional 957 shares during the period. Rational Advisors LLC grew its holdings in Mylan by 1,111.0% during the second quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock worth $42,000 after purchasing an additional 2,011 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Mylan by 92.9% during the third quarter. Steward Partners Investment Advisory LLC now owns 2,367 shares of the company’s stock worth $46,000 after purchasing an additional 1,140 shares during the period. CSat Investment Advisory L.P. increased its position in Mylan by 258.9% during the second quarter. CSat Investment Advisory L.P. now owns 2,835 shares of the company’s stock worth $54,000 after buying an additional 2,045 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in Mylan by 570.7% during the third quarter. Parallel Advisors LLC now owns 2,998 shares of the company’s stock worth $59,000 after buying an additional 2,551 shares during the last quarter. Hedge funds and other institutional investors own 86.54% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: Are FAANG stocks a good investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.